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Single institution implementation of permanent
131Cs interstitial brachytherapy for previously
irradiated patients with resectable recurrent head
and neck carcinoma
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States, 4Department of Radiation Oncology, William Beaumont Hospital, Royal Oak, MI, United States

Abstract
Purpose: Permanent interstitial brachytherapy is an appealing treatment modality for patients with locoregional
recurrent, resectable head and neck carcinoma (HNC), having previously received radiation. Cesium-131 (131Cs) is
a permanent implant brachytherapy isotope, with a low average photon energy of 30 keV and a short half-life of
9.7 days. Exposure to medical staff and family members is low; patient isolation and patient room shielding are not
required. This work presents a single institution’s implementation process of utilizing an intraoperative, permanent
131Cs implant for patients with completely resected recurrent HNC.
Material and methods: Fifteen patients receiving 131Cs permanent seed brachytherapy were included in this analysis. The process of pre-planning, selecting the dose prescription, seed ordering, intraoperative procedures, post-implant planning, and radiation safety protocols are described.
Results: Tumor volumes were contoured on the available preoperative PET/CT scans and a pre-implant treatment
plan was created using uniform source strength and uniform 1 cm seed spacing. Implants were performed intraoperatively, following tumor resection. In five of the fifteen cases, intraoperative findings necessitated a change from the
planned number of seeds and recalculation of the pre-implant plan. The average prescription dose was 56.1 ±6.6 Gy
(range, 40-60 Gy). The average seed strength used was 2.2 ±0.2 U (3.5 ±0.3 mCi). Patients returned to a recovery room
on a standard surgical floor and remained inpatients, without radiation safety restrictions, based on standard surgical
recovery protocols. A post-implant treatment plan was generated based on immediate post-operative CT imaging to
verify the seed distribution and confirm delivery of the prescription dose. Patients were provided educational information regarding radiation safety recommendations.
Conclusions: Cesium-131 interstitial brachytherapy is feasible and does not pose major radiation safety concerns; it
should be considered as a treatment option for previously irradiated patients with recurrent, resectable HNC.
J Contemp Brachytherapy 2019; 11, 3: 227–234
DOI: https://doi.org/10.5114/jcb.2019.85778
Key words: interstitial, brachytherapy, cesium-131, head and neck cancer, salvage treatment.

Purpose
Head and neck cancer is the sixth most common cancer worldwide [1,2]. Over 800,000 new head and neck
cancer cases are diagnosed and nearly 450,000 head and
neck cancer-related deaths occur annually worldwide,
as of 2018 [1,2]. About two thirds of patients with head
and neck carcinoma (HNC) are diagnosed at an advanced
stage of the disease [3]. Surgical resection followed by radiotherapy or post-operative chemoradiation/definitive

chemoradiation are employed as treatment modalities,
with curative intent for patients with locally advanced
disease. Unfortunately, the likelihood of treatment failure for patients with locally advanced HNC remains
high, reaching 50%, with locoregional failure and distant
metastases occurring in 20-30% of patients [3,4,5,6,7,8].
Locoregional failure has remained the predominant pattern of failure and it is the most common cause of death
in HNC patients [9,10]. Patients with recurrent or met-
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astatic HNC have a poor prognosis, with median overall survival of less than one year [8,11,12], necessitating
a pressing need to improve therapy for patients with recurrent HNC.
Prognosis is particularly poor when the recurrence
develops in an area previously treated with radiation
[11,12]. Salvage surgery in previously irradiated cases
can provide durable disease control in 15% of patients
with locoregional recurrence in the absence of disease at
distant sites [3]. Nevertheless, the pathological findings
following salvage surgery frequently indicate that the patient requires a second course of post-operative radiation
due to the unclear or positive surgical margins or other
adverse pathologic features [3,13].
Due to technological advances in radiation oncology
in the recent years, re-irradiation using external beam
radiation therapy (EBRT) has become an option. Unfortunately, most studies involving EBRT for re-irradiation
are retrospective and report on a small patient cohort and
a single institution experience; the treatment regimens
and patient characteristics vary considerably between
studies. Moreover, the treatment-related toxicity may be
very significant and may include surgical wound healing
complications, fistula formation, osteoradionecrosis, vascular events, transverse myelitis, brainstem and cranial
nerve injury, etc. [3,12,14].
Brachytherapy has significant advantages over external beam radiation therapy, thus should be considered
when a second course of radiation is indicated [15]. Compared to EBRT, brachytherapy facilitates the delivery of
a high and localized radiation dose to the target volume.
The dose to the surroundings tissues is significantly reduced due to the characteristic rapid dose falloff [13]. The
reduced radiation delivery time of brachytherapy relative
to conventionally fractionated EBRT may increase the effectiveness of radiotherapy; in particular head and neck
cancer is known to have relatively short radiobiologically
estimated repair half-life. Furthermore, given that the hypoxic mass of the tumor is removed during salvage surgical resection, hypothetically, only well-oxygenated microscopic disease remains around the surgical margins.
Therefore, a lower radiation dose could be sufficient with
the use of brachytherapy [16].
Inorganic Core w/131Cs attached
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(0.25 mm OD)
Titanium case
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Fig. 1. Proxcelan™
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Material and methods
Patients were treated per an institutional protocol
for recurrent resectable HNC. Fifteen patients receiving
131Cs permanent seed brachytherapy were included in
this analysis.

Description of the experimental product
IsoRay™ (Richland, WA) provides the sterilized
Proxcelan™ 131Cs [23] seeds used in all implants in either
strands or a mesh. Seeds contain an inorganic substrate
adsorbed with the radioactive 131Cs isotope and a 4 mm
radio-opaque gold marker encased in a 0.05 mm titanium capsule, as seen in Figure 1. The outer diameter and
length of the capsule are 0.82 mm and 4.5 mm, respectively. The vendor manufactures the seeds and places them
into 3-0 vicryl strands at 1 cm intervals or in a mesh with
user-defined spacing and positioning. The strands or
mesh can then be sutured directly into the resection bed.

Implant pre-planning and dose prescription

0.65 mm

Laser welded ends
(0.10 mm wall)

The majority of the published brachytherapy results
were obtained with low-dose-rate, high-dose-rate, or
pulsed-dose-rate techniques and manual afterloading
[17,18,19,20,21,22]. Compared to other isotopes, Cesium-131 (131Cs) is a relatively new permanent seed implant
brachytherapy isotope, with an average photon energy of
30 keV and short half-life of 9.7 days [23]. Compared to
external beam radiation or high-dose-rate brachytherapy
using Iridium-192, the lower energy photons from 131Cs
decay allow for more localized deposition of dose, decreasing the dose delivered to nearby tissues, and potentially reducing treatment complications. The feasibility of
131Cs implants for recurrent HNC has been demonstrated
with acceptably low levels of exposure to staff during the
procedure [24]. In a small series, re-irradiation using permanent 131Cs has been shown to provide similar rates of
survival with decreased toxicity, compared to prior literature [25].
The purpose of this report is to describe a single institution’s implementation process of utilizing intraoperative, permanent 131Cs seed implants for patients
with completely resected recurrent HNC. The process of
pre-planning, pre-implant seed ordering, intraoperative
procedures, post-implant planning, and radiation safety
protocol are described.

Tumor volumes were identified on a preoperative
positron emission tomography/computed tomography
(PET/CT) scan. The estimated size and location of the
resection cavity were estimated by the radiation oncologist and otorhinolaryngology surgeon, and the optimal
plane to suture stranded seeds or a mesh was identified.
A surgical mesh is available for purchase with customizable seed and strand spacing. The constructed mesh is
then provided to the institution sterilized. The decision
to utilize stranded seeds or a predesigned mesh depends
on surgeon preference as well as implant location. An implant that spans across the carotid artery is an example
of one location that may benefit from strands of seeds in-
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stead of a mesh, allowing for strands to be individually
sutured on either side of the critical structure with adequate spacing.
Using MIM Symphony LDR™ treatment planning
software, version 6.5 (Cleveland, OH, USA) [26,27], the
seeds were placed in a single, optimal plane with 1 cm
seed-to-seed spacing to cover the estimated resection cavity. The seed air kerma strength was iteratively adjusted
in the planning software, such that a dose of 60 Gy was
delivered to a prescription located 5 mm perpendicular
to the center of the implant plane. Planning details have
previously been reported [28]. The treatment plan was
reviewed by the medical physicist, radiation oncologist,
and otorhinolaryngology surgeon. The prescription dose
was decreased in cases where there was a concern for
normal tissue toxicity by the radiation oncologist. In most
cases, especially those with larger uncertainty in the size
or geometry of the estimated resection cavity, an extra
strand of seeds was ordered.

Seed ordering and receipt
Sources were ordered five to seven business days
prior to implant date from IsoRay™ for each patient.
Radioactive materials were delivered to the radiation
safety office per institutional protocols, including wipe
tests and source inventory recording. Sources were then
transferred to the department of radiation oncology, accepted by a medical physicist, logged in the source inventory, and stored in a secure location designated for
radioactive material. Non-sterile, loose seeds from the
same lot as the implant seeds were ordered and assayed
for verification of vendor-stated activity. The number of
assayed seeds was either 10% of the number of seeds in
the implant or five seeds, whichever was larger [29]. Assays were performed using an accredited dosimetry calibration laboratory-calibrated HDR 1000 Plus well-type
ionization chamber and Max-4000 electrometer for each
patient seed order prior to implant, with an average difference of 1.2 ±1.1% from vendor-specified activity. This
was documented by a medical physicist and included in
the patient’s chart. The un-assayed sources for implant
remained in the sterile packaging from the vendor and
were transported to the operating room under the supervision of a medical physicist after the completion of the
surgical resection. Cesium-131 storage is restricted and
based only upon institutional policies and governmental
regulations for storing radioactive material; there are no
limitations on environmental conditions such as light or
temperature.
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The number of sources was verified for each patient
by the AU (authorized user – a qualified radiation oncologist) and medical physicist intraoperatively prior
to insertion. The surgical bed was carefully explored by
the radiation oncology and surgical oncology teams, and
the carotid artery or other major vessels, bones, or cranial nerves were identified. In order to reduce the risk of
carotid rupture, osteoradionecrosis, and neuropathies,
the seeds were carefully positioned into the surgical bed,
avoiding direct contact with the carotid artery, bone, or
cranial nerves. The surgeon and radiation oncologist
(AU) placed the 131Cs seeds in an appropriate orientation
within the resection bed. The seed strands or mesh were
secured with surgical clips or sutured by the otorhinolaryngology surgeon and the surgical team continued with
the standard wound closure and/or flap reconstruction
(Figure 2).
Flap reconstructions are performed in some HNC resection cases regardless of the use of brachytherapy implants; they did not represent additional interventions in
these patients. Preparation of the flap reconstruction was
performed before the seeds were implanted into the surgical bed in order to reduce the exposure of the surgical
team. Flap coverage is the standard of care for head and
neck reconstruction for salvage surgery of patients with
recurrent disease, having previously received radiation
to the surgical site in order to reduce the risk of fistula formation and tissue breakdown post-operatively. Free flaps
or pedicled myofascial flaps covered the brachytherapy
implants and brought radiation-naïve tissue to the resection bed to promote wound healing. Standard monitoring of the reconstructed flap and/or surgical wound
followed the standard institutional protocol.

B
A

Intraoperative procedures
Implants were performed intraoperatively, immediately following tumor resection. Patients underwent
maximally safe resection of the tumor as determined by
the otorhinolaryngology surgeon. At the time of resection, the location and size of the removed tumor (maximum diameter and volume), the relationship to the
surrounding normal structures, and the frozen surgical
margins were reviewed and compared to the pre-implant
treatment plan.

Fig. 2. A) Five strands of either three or four seeds, totaling 18 seeds, were implanted for patient 6 following the
neck dissection for locoregional recurrence; B) A pec flap
was used in this case for reconstruction to bring radiation-naïve tissue to the resection bed
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Cesium-131 was added to our institution’s radiation
safety license isotope list for quantities necessary for per-

manent implant brachytherapy for patients with recurrent resectable HNC. Radiation oncologists were defined
as AU by the radiation safety office, in accordance with
state legislature and institutional policy for competency
in manual brachytherapy. Nursing staff, residents, and
physicians participating in clinical care for these patients in the operating room, recovery area, or hospital
floor received radiation safety refresher training with
an emphasis on the properties of the 131Cs isotope and
the implanted sites of the head and neck region. Median
equivalent dose to surgeons’ hands was measured using
a ring badge for each of the first six cases individually.
For subsequent cases, the surgeons were assigned ring
badges, which were read quarterly. Additional staff were
assigned body or ring dosimeters as deemed appropriate
by radiation safety.
Pre- and post-implant radiation surveys of the patient
were performed using a Fluke 451B ionization chamber
survey meter by the medical physicist. The post-implant
survey was performed after final wound closure. Radiation exposure was measured at 1 m from the surgical site.
Educational information, including instructions regarding radiation safety recommendations were provided to the clinical staff in the operating room. Instructions
were subsequently handed off to the recovery room and
the medical floor nursing teams. Patients returned to the
recovery room, then regular surgical floor, and remained
inpatients following the standard surgical recovery protocols. Due to the photon energy of 131Cs and implanted activity needed to achieve the desired therapeutic doses, no
special room or patient precautions were necessary as all
patients met the United States Nuclear Regulatory Commission (NRC) criteria for release of patients administered
radioactive material. No shielding was added to the im-

A

B

Although the prescription dose and number of seeds
were calculated during a preoperative planning session,
the number of seeds implanted was modified intraoperatively to fit the surgical defect and the at-risk area to be
covered in some cases. Modifications were determined
jointly by the radiation oncology and surgical oncology
teams. Additionally, in cases where modifications were
large, the radiation prescription dose was also lowered
intraoperatively.
Implanted number and activity of seeds were documented on the written directive completed at the end of
the implant by the AU and the medical physicist. Sources
not used in the procedure were returned to the radiation
oncology radioactive storage area, logged in the radiation
source inventory, and stored for decay per existing institutional policies.

Post-implant treatment planning and dose
calculation
A non-contrast CT scan with 0.7-2.0 mm thick slices
and O-MAR artifact reduction protocol was performed
within 24 hours after the implant for all patients. Patients
2-5, 10, and 14 were scanned on a Philips Brilliance 64
scanner with 2.0 mm thick slices. Patients 1, 6-9, 11-13,
and 15 were scanned on a Philips iCT 256 scanner with
0.7-2.0 mm thick slices. The implanted seeds were identified on the post-implant CT, and a post-implant treatment plan was created to confirm the seed location and
delivered prescription dose. Figure 3 displays the pre-implant and post-implant treatment plan for patient 6.

Radiation safety

Fig. 3. A) The pre-treatment treatment plan for patient 6. Seed activity of 2.1 U was selected to deliver 60 Gy to 0.5 cm from the
center of the implant plane; B) The post-implant treatment plan in created by identifying the seeds on the post-implant CT scan.
In this case, the number of implant seeds and the prescription dose did not change based on intraoperative findings
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plant site in any of these 15 patients. All patients were educated prior to implantation on the risk and safety concerns
regarding radiation exposure. Patients were provided
written educational information as part of their discharge
instructions regarding radiation safety recommendations.

Statistical methods
The mean and standard deviation were calculated
for the number of seeds, individual seed strength, and
final prescription dose for 15 patients. A range of minimum-maximum values was also reported. Generally, for
radiation safety and personnel dosimetry, mean, standard
deviation, and range are reported for the patient survey for
15 implants, and the mean and range of the surgeons’ ring
badge reading are reported for the first six cases.

Results
The average seed strength used for implants was 2.2
±0.2 U (range, 1.7-2.5 U; 3.5 ±0.3 mCi; range, 2.7-3.9 mCi).
In five of 15 cases, the number of seeds implanted was
modified intraoperatively to fit the surgical defect and
the at-risk area to be covered. In three cases, the radiation prescription was lowered intraoperatively. In two of
those three cases, the change in number seeds implanted necessitated a prescription change. In the other case
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(patient 14), it was initially planned that 17 seeds would
be implanted in a single site to deliver 60 Gy. However,
intraoperative findings led the surgical and radiation oncology teams to alter the prescription such that 40 Gy was
delivered to two separate sites, with 6 seeds in one location and 11 in the other. The average final prescription
dose for 15 patients was 56.1 ±6.6 Gy (range, 40-60 Gy) to
5 mm from the center of the implanted plane, and an average of 14 ±6 (range, 4-24) seeds were implanted. Table 1
presents the seed strength, and the pre- and post-implant
dose prescriptions as well as number of seeds used. Intraoperative changes in early cases were attributed to
the learning curve of the clinicians; improved communication between the surgeon and the radiation oncology
teams about the estimated size and geometry of the resection cavity decreased the number of deviations between
pre- and post-planned prescriptions and the number of
seeds implanted.

Radiation safety
For the pre-implant survey, the exposure rate at 1 m
was < 0.1 mR/hr for all patients, which is the expected
background level of radiation. Following implantation of
the radioactive sources and conclusion of the surgery, the
exposure rate was measured again at 1 m from the surgical site, yielding an average of 1.5 ±1.0 mR/hr (0.1-4.0

Table 1. Seed activity, dose prescription, and number of seeds from the pre- and post-plans for all 15 patients,
listed in chronological order. Intraoperative changes in the dose prescriptions and number of seeds are indicated
Patient

Seed strength
(U)

Pre-implant plan

Post-implant plan

Dose
prescription
(Gy)

Number
of seeds

Dose prescription (Gy)

Number
of seeds

Intraoperative change
Dose prescription (Gy)

Number
of seeds

1

1.7

60

30

60

24

2

1.7

66

48

54

20

–12

–28

3

2.3

60

9

42

4

–18

–5

4

2.3

60

15

60

15

5

2.5

60

9

60

9

6

2.1

60

18

60

18

7

2.2

60

22

60

22

8

2.4

60

6

60

6

9

2.0

56

14

56

14

10

2.4

60

8

60

10

11

2.2

50

7

50

7

12

2.4

60

12

60

12

13

2.0

60

20

60

20

14

2.2

60

17

40

17

15

2.2

60

13

60

17

Mean

2.2

59.5

16.5

56.1

14.3

Median

2.2

60.0

14.0

60.0

15.0

SD

0.2

3.1

10.5

6.6

5.9
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mR/hr). Median equivalent dose to surgeons’ hands was
0.60 mSv (range, 0.33-1.48 mSv) for the first six cases.
Subsequent quarterly thermoluminescent dosimetry
(TLD) ring and optically stimulated luminescence (OSL)
body badge measurements were well below acceptable
ALARA (as low as reasonably achievable) dose limits.

Discussion
Surgical resection, when feasible, remains the mainstay treatment for recurrent HNC, and intraoperative
interstitial brachytherapy delivered as an adjuvant treatment for this group of patients may improve the treatment outcome and may be associated with fewer complications, when compared with EBRT re-irradiation [30,31].
The use of interstitial brachytherapy remains limited
in recurrent HNC despite numerous successful published
reports. This is perhaps due to the lack of familiarity and
experience with implantation techniques and/or concerns about radiation exposure to personnel. Brachytherapy can be delivered via permanent implants or via the
insertion of high-activity radioisotopes through removable catheters (using high-dose-rate brachytherapy or
pulsed-dose-rate brachytherapy). Permanent implants
may be more appropriate and advantageous for recurrent
HNC patients, as their recurrences often occur in irregular surfaces that may not be suitable for or may pose
challenges for catheter-based brachytherapy [31,32].
Moreover, recent success with safer ultra-low doserate isotopes has re-stimulated interest in permanent interstitial brachytherapy and prompted our use in recurrent head and neck malignancies [33,34,35,36].
Cesium-131 is a favorable isotope for use across
a wide range of tumors and its dose distribution properties facilitate easy calculation and delivery in the clinic
[23,24]. Cesium-131 decays via electron-capture and generates photons with prominent peaks in the 29 to 34 keV
range. The average photon energy is greater than other
commonly used permanent seed implant isotopes, namely Palladium-103 (103Pd) and Iodine-125 (125I), which has
been shown to improve dose homogeneity in some implants [37]. Moreover, 131Cs has a half-life of 9.7 days,
which is shorter than 103Pd and 125I, delivering the prescribed dose in less time and decreasing the overall exposure to the patient and family. Additionally, a shorter
half-life improves the quality of the implant by delivering
dose faster and limiting the time period where seed migration caused by wound healing could interfere with the
planed dose distribution [23,24,37].
A major benefit of brachytherapy over external beam
radiation therapy in previously irradiated areas is the extremely localized deposition of dose. With 131Cs, the dose
is prescribed to 0.5 cm from the implant plane, and the
dose falls off to less than 10% of prescription, approximately 2-3 cm in all directions from the implant plane.
This dose fall-off and the associated preservation of
healthy tissues is unachievable even with the most technologically advanced external beam radiation delivery
techniques [38].
While pre-planning, it is necessary to estimate the
seed strength and the number of seeds to be implanted;

the extent of the surgical resection can result in drastic
anatomical changes from the pre-implant imaging. Thus,
the number of seeds implanted based on the size and location of the surgical cavity was adjusted intraoperatively in five of these first fifteen cases, and the prescription
dose was decreased in three of the five adjusted cases.
This reflects the learning curve in anticipating the geometry of the resection cavity and emphasizes the need for
communication with the surgical team for the purpose of
pre-planning and seed ordering.
The risk of radiation exposure to the health care personnel and patient family members is negligible, and the
use of 131Cs brachytherapy does not require additional
shielding or patient precautions based on the prescription doses, the total implanted activity, and the location
of sources used in these patients. Appropriate educational
information is provided to the health care professionals
taking care of these patients intra- and post-operatively.
Discharge instructions regarding radiation safety recommendations are given to the patients and their family. Our
radiation safety data is promising and coincides with the
previously published experience. Parashar et al. treated
28 patients with recurrent HNC and brain tumors, using
131Cs sources with a median activity of 2.4 U for a total
prescribed dose of 60-80 Gy. In this cohort, the median radiation exposure rate at the patient skin was 0.43 mSv/hr
and at 1 meter the exposure was 0.002 mSv/hr. The minimum measurable radiation dose for OSL body badges and
TLD ring badges was 1 mrem and 30 mrem, respectively.
Overall, the exposure to radiation oncologist, surgeons,
and nursing staff was determined to be minimal [24].
Implementation of this procedure requires minimal
equipment and staff resources if an existing brachytherapy program is in place. Most low-dose-rate brachytherapy software programs are capable of calculating a basic
treatment plan or secondary dose verification for this
procedure. Additionally, a nomogram may be an acceptable substitute for a secondary dose calculation in lieu of
a formal dose calculation [28]. Point dose dosimetry was
applied uniformly to all pre- and post-planning due to the
nature of source placement and the inability to accurately decipher source orientation on post-implant imaging.
While permanent implant brachytherapy is common in
radiation oncology, this may be a new procedure for other clinical staff involved in an HNC patient’s care. Thus,
an appropriate introduction into radiation safety and permanent seed implants across the care team is essential.
The radiation dose prescribed by our group concurs
with that used by other radiation oncology centers in
the setting of resectable recurrent HNC. A group at MD
Anderson published their work using 192Ir interstitial
brachytherapy with median dose of 60 Gy over a total
duration of 4 days, with salvage surgery for 22 patients
with recurrent head and neck cancers [33]. All patients
underwent neck dissection and intraoperative placement
of high-dose-rate brachytherapy afterloading catheters
as a part of the salvage treatment. Of the 22 patients,
19 had extensive extracapsular spread at the time of surgery. Post-operative complications were few, and there
were no perioperative deaths. Recurrences in the re-irradiated necks occurred in 27% of patients. The 2-year re-
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gional control reported by this study was 57%, with a median time for recurrent disease of 19 months [33]. Grimard
et al. found similar results by using brachytherapy for
recurrent head and neck malignancies; irradiation with
brachytherapy was used as a single-modality treatment
in almost one half of the patients, with a dose of 60 Gy
received by 18 of 22 patients (with all patients receiving
> 55 Gy). Twenty of the remaining patients had surgical
resection in addition to brachytherapy; the 1 year and
2 years locoregional control was 50% and 37%, respectively, with acceptable rates of toxicity [34]. Puthawala
et al. used 192Ir interstitial afterloading brachytherapy delivering a median minimum dose of 53 Gy without surgery (40% received concurrent chemotherapy or a radiosensitizing agent) in the setting of recurrent neck disease,
demonstrating a six month local tumor control of 77%;
however, moderate to severe complications occurred in
27% of the patients [35]. Similarly, Glatzel et al. reported
a complete remission rate of only 28% in 51 patients with
recurrent HNC treated with high-dose-rate brachytherapy alone without surgical resection, with a median overall survival of only 6 months [36].
A new technique, intensity modulated brachytherapy (IMBT) has been used with promising results for the
treatment of sinonasal carcinomas and tumors invading
the skull base and recurrent HNC. The image-guided
adapted planning ensures the correct radiation sources
position and respects the dosimetric constrains to the surroundings normal structures, possibly further reducing
the risk of severe complications [10,13,39]. Teudt et al.
used HDR-IMBT for nine patients with recurrent HNC
into the cervical lymph nodes [10].
The 131Cs seed implant is permanent and unlike highdose-rate brachytherapy, does not require the catheters to
be placed into the surgical bed and maintained in place for
several days post-operatively until treatment is complete.
This permanent implant reduces the risk of infection by
eliminating the need for in-place catheters and additional
surgical intervention to remove them. Surgical resection
and the 131Cs implant occur during the same surgical procedure, and no further surgical intervention is required.
The surgical bed is defined by the surgical and radiation
oncology teams intraoperatively, and the seeds strands
are secured into the surgical bed, at that time. The technique is easy to implement and requires minimal equipment and staff resources; the risk of radiation exposure
to the health care personnel and patient family members
is negligible. From our data and that in previously published literature, the use of 131Cs brachytherapy does not
require additional shielding or patient precautions; however, this may depend on the position of sources and the
amount of surrounding tissue [23,24]. A disadvantage
of permanent implant brachytherapy compared to other
forms of brachytherapy or EBRT is the inability to modulate or control the dose distribution.
Re-irradiation using external beam radiation may be
used alone or in combination with surgery or systemic
therapies, but is associated with significant risk for fistula formation, severe dysphagia, and carotid ruptures, as
previously discussed [40,41,42].
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Prospective clinical trials eliminating the patient’s
tumor and treatment characteristics’ heterogeneity are
necessary, but unlikely to be done given the rare use
of these options. The final therapeutic choice should
depend on a careful review of each individual case in
a multidisciplinary treatment approach setting, paying
attention to the general performance status of the patient and his/her emotional condition, tumor location
and its relationship with the surrounding critical structures, previous radiotherapy dose delivered to this area,
the experience of the treating team, and the available
treatment facilities.

Conclusions
Cesium-131 interstitial brachytherapy is a feasible
treatment option for previously irradiated patients with
recurrent, resectable HNC. It should be considered as
a viable alternative to external beam radiation. Permanent
seed implants using 131Cs do not pose radiation safety
concerns to the surgical and nursing staffs, or to patients
and their family members. Although our current work focuses on the process of safely treating locoregional recurrent, resectable HNC patients with 131Cs brachytherapy,
future work will emphasize the utilization of this form
of therapy as a viable treatment option overcoming the
negative side effects of re-irradiation using external beam
with or without the combination of surgery and systemic
therapies for the same patient population.
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